Researchers from the University of Adelaide in collaboration with medical technology company Fertilis have developed a new microdevice that will allow more IVF clinics to offer intracytoplasmic sperm injection (ICSI) as a treatment.
ICSI is a slow and complicated procedure that involves inserting a single sperm into an egg for fertilization, and can only be performed by experienced embryologists.
The device will also help improve several IVF procedures such as embryo culture, cryopreservation of embryos and in vitro maturation.
This new technology – said to be smaller than a pinhead – holds up to 10 eggs in individual positions for faster injection, allowing embryologists to more easily track and avoid the risk of errors.
Lead researcher Dr. Kylie Dunning of the University of Adelaide’s Robinson Research Institute said the device would halve treatment time, require less training for embryologists with less expensive equipment than current ICSI treatment, and improve access to procedures for more procedures.
“Developing this new, innovative approach is an important breakthrough for people who want to start a family who have failed to do so because of male infertility,” Dr. Dunning said.
“By eliminating the need for a pipette that normally contains an unfertilized egg during ICSI, this device simplifies the injection process, reduces reliance on high technical expertise, and greatly improves embryo production.
“This discovery removes significant barriers to treating people with infertility and improving IVF success.”
The inventor of the device and co-founder of Fertilis Professor Jeremy Thompson said his company is very excited to bring the breakthrough device to market.
“Where IVF science has succeeded, technology has tended to stagnate – so far,” Thompson said.
“ICSI has not changed since its inception 30 years ago. Continuous innovation in such an IVF lab is the only way to increase success and reduce the financial and emotional burden on patients. ”
The device will undergo global clinical trials in 2022. The project was supported by the Australian Research Council and The Hospital Research Foundation Group. Paul Flynn, the hospital’s chief executive of the research team, said the organization proudly supports Dr. Dunning’s research over the past three years to improve IVF’s success rates.
“This device should change the game for the thousands of parents who hope, who need to rely on ICSI,” Flynn said.